PAMS
MCRB icon

Pictet Asset Management (Switzerland)’s Seres Therapeutics MCRB Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$65.6K Hold
685
– – ﹤0.01% 1918
2023
Q1 		$77.6K Hold
685
– – ﹤0.01% 1910
2022
Q4 		$77K Buy
+685
New +$91.8K ﹤0.01% 1914

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s MCRB Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) held its Seres Therapeutics (MCRB) position steady in Q2 2023 at 685 shares worth $65.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1918.

Pictet Asset Management (Switzerland) first reported a position in MCRB in Q4 2022 and has held it in 3 quarters since. The position peaked at $77.6K in Q1 2023. 137 funds tracked by Wall St. Rank hold MCRB as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 685 shares of Seres Therapeutics worth $65.6K as of Q2 2023.
  • Pictet Asset Management (Switzerland) left its Seres Therapeutics share count unchanged in Q2 2023.
  • Seres Therapeutics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1918 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Seres Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • Pictet Asset Management (Switzerland)'s Seres Therapeutics position peaked at $77.6K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.